Selection of HLA-A2 restricted CML28 peptide by artificial antigen-presenting cells

Abstract

Chronic myelogenous leukemia (CML) 28 is a broadly immunogenic antigen that can have an antileukemia effect. We adopted the SYFPEITHI database to predict human leukocyte antigen-A2 restricted CML28 peptide. We designed artificial antigen-presenting cells (aAPCs) by coating micro beads with human leukocyte antigen-A2-immunoglobulin dimer and CD28-specific antibody. We used the selected peptides-pulsed aAPCs to induce cytotoxic T lymphocytes (CTLs), to choose the CML28 peptide, which was best for inducing CTLs. The result showed that the peptides-pulsed aAPCs could induce CTLs and that the peptide VLTFALDSV was the best choice for significantly inducing specific CTLs.